IMUGENE LIMITED — Board/Management Information 2025

May 29, 2025

==> picture [177 x 31] intentionally omitted <==

ASX Announcement

Dr John Byon appointed Chief Medical Officer

• Dr Byon has extensive experience leading the clinical development of innovative CAR-T and CAR-NK therapies for multiple hematologic malignancies at Fate Therapeutics, Lyell Immunopharma, Juno Therapeutics as well as development of atezolizumab at Genentech.

• Dr Byon was instrumental in developing Imugene’s strategy to combine azer-cel with IL-2, significantly improving efficacy and durability in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Sydney, Australia, 30 May 2025: Imugene Limited (ASX: IMU), a clinical-stage immunooncology company, is pleased to announce the appointment of Dr John Byon, MD, PhD, as the Company's Chief Medical Officer (CMO), effective immediately.

Dr Byon is an accomplished physician-scientist and executive leader with extensive experience in clinical development and cancer immunotherapy, particularly in CAR-T cell therapy. He joined Imugene in September 2023 as Senior Vice President, Clinical Development and in his time with the Company has been instrumental in development across the entire pipeline especially in pioneering the combination approach of Imugene’s allogeneic CAR-T therapy, azer-cel, with interleukin-2 (IL-2). This significantly enhances the therapeutic efficacy and durability (length of time patient experiences a positive response to treatment) of responses observed in the ongoing Phase 1b trials for

relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The strategic inclusion of IL2 has also proven critical in achieving impressive complete response rates (no sign of cancer), showcasing a meaningful therapeutic option for patients who previously experienced treatment failure with conventional therapies, including autologous CAR-T treatments.

Dr Byon joined Imugene from Fate Therapeutics, where he most recently served as Vice President, Clinical Development, Hematology, overseeing a comprehensive portfolio of innovative CAR-NK and CAR-T cell therapies targeting multiple hematologic

malignancies, including acute myeloid leukemia (AML) and multiple myeloma (MM). His

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

==> picture [42 x 42] intentionally omitted <==

extensive industry experience also spans significant roles at Lyell Immunopharma, Juno Therapeutics, and Genentech, where he successfully progressed multiple therapeutic candidates from preclinical stages through pivotal clinical trials. He has consulted for biotech and major pharmaceutical companies for blood cancer therapies demonstrating robust expertise in translational medicine, regulatory strategy, and clinical trial execution.

Dr Byon’s appointment follows the resignation of Dr Paul Woodard, who is stepping down from the CMO role. The Board and management extend their sincere gratitude to Dr Woodard for his outstanding service and contributions to Imugene.

Leslie Chong, Managing Director and CEO of Imugene, said:

“We are very pleased to see Dr Byon become our new Chief Medical Officer. His extensive background in oncology drug development and pivotal role in conceptualising and driving the strategic combination of azer-cel with IL-2 is indicative of his innovative approach and deep commitment to advancing cancer treatments. Dr Byon is a trained

hematologist-oncologist and a scientist who has worked extensively in biotech and pharmaceutical companies developing therapies for patients in need. His scientific acumen, strategic insight, and proven leadership in clinical development will be invaluable as Imugene continues to progress its clinical pipeline towards commercialisation.”

Dr Byon holds both a Doctor of Medicine and Doctor of Philosophy from Tulane University, in addition to a Bachelor of Science from the Massachusetts Institute of Technology. His career includes numerous leadership positions focusing on clinical development and translational medicine, with particular expertise in regulatory affairs, clinical strategy formulation, biomarker integration, and leading high-performance, cross-functional clinical teams.

For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

info@imugene.com

IMUGENE LIMITED ACN 009 179 551

2

==> picture [42 x 42] intentionally omitted <==

General Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

Matt Wright matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited Follow us on Twitter @TeamImugene Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.

IMUGENE LIMITED ACN 009 179 551

3